GREY:ATBPF - Post by User
Post by
MrMugsyon Jan 11, 2021 8:07am
229 Views
Post# 32265420
Corporate Update ... didn't learn much
Corporate Update ... didn't learn muchDan brought his sparkler - vague
The only thing I hear is ... delay
- Partnering interest is up
- P3 prep work is on schedule with 8 studies completed - 2 ongoing
- Delayed P3 a quarter or two due to COVID ... that can only get worse IMO
- Submitting IND within weeks - again with the vague "weeks" comment
- Peak annual sales for 352 is expected to be $800M in USA alone
- Pipeline expansion initiative is now generating promising new molecules and fresh IP - more details in the coming months
- Development of new molecules is an ongoing process - announce progress in the coming months
- First candidate for in vivo tesing targets IBD
- intensifying our focus on increasing the value of our assets and improving negotiating leverage
- January is the launch of our large marketing partnering program
- Outreach to 70 global and regional pharma firms - report material developments as they occur (this is different than the outreach program ???)
- Soon to upgrade the OTC listing to the QX from a QB level designation